NRIXNurix Therapeutics, Inc.

Nasdaq nurixtx.com


$ 12.36 $ 0.00 (0 %)    

Friday, 26-Apr-2024 15:59:56 EDT
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 12.36
$ 12.21
$ 12.34 x 200
$ 0.00 x 0
$ 12.20 - $ 12.60
$ 4.22 - $ 18.12
599,965
na
678.61M
$ 1.15
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-10-2024 02-29-2024 10-Q
2 02-15-2024 11-30-2023 10-K
3 10-12-2023 08-31-2023 10-Q
4 07-13-2023 05-31-2023 10-Q
5 04-13-2023 02-28-2023 10-Q
6 02-09-2023 11-30-2022 10-K
7 10-06-2022 08-31-2022 10-Q
8 07-07-2022 05-31-2022 10-Q
9 04-08-2022 02-28-2022 10-Q
10 01-28-2022 11-30-2021 10-K
11 10-14-2021 08-31-2021 10-Q
12 07-13-2021 05-31-2021 10-Q
13 04-13-2021 02-28-2021 10-Q
14 02-16-2021 11-30-2020 10-K
15 10-14-2020 08-31-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-jpmorgan-shares-are-trading-lower-by-around-5-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of JPMorgan Chase & Co. (NYSE: JPM) fell sharply during Friday’s session following first-quarter earnings.

 applied-digital-reports-downbeat-results-joins-nurix-therapeutics-and-other-big-stocks-moving-lower-in-fridays-pre-market-session

U.S. stock futures were lower this morning, with the Dow futures falling over 50 points on Friday.

 why-nextplat-shares-are-trading-higher-by-around-30-here-are-20-stocks-moving-premarket

Shares of NextPlat Corp (NASDAQ: NXPL) rose sharply in today’s pre-market trading after the company reported consolidated 2023...

 nurix-therapeutics-prices-upsized-175m-public-offering-of-10166667-common-shares-at-15share

Nurix Therapeutics, Inc. (NASDAQ:NRIX) today announced the pricing of its upsized underwritten public offering of 10,166,667 sh...

 nurix-therapeutics-commences-public-offering-of-125m-of-its-common-stock-and-in-lieu-of-common-stock-in-case-of-certain-investors-pre-funded-warrants-to-purchase-shares

Nurix currently intends to use any net proceeds from this offering primarily to fund clinical development of its drug candidate...

 why-fastenal-shares-are-trading-lower-by-around-7-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter f...

 rbc-capital-maintains-outperform-on-nurix-therapeutics-raises-price-target-to-23

RBC Capital analyst Gregory Renza maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target f...

 enliven-therapeutics-alpine-immune-sciences-janux-therapeutics-and-other-big-stocks-moving-higher-on-thursday

U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NA...

 baird-maintains-outperform-on-nurix-therapeutics-raises-price-target-to-25

Baird analyst Joel Beatty maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $24 ...

 needham-reiterates-buy-on-nurix-therapeutics-maintains-31-price-target

Needham analyst Gil Blum reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $31 price target.

 nurix-therapeutics-q1-gaap-eps-076-beats-080-estimate-sales-1659m-miss-1664m-estimate

Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(...

 needham-reiterates-buy-on-nurix-therapeutics-maintains-31-price-target

Needham analyst Gil Blum reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $31 price target.

 nurix-therapeutics-reports-first-clinical-evidence-of-cns-activity-of-nx-5948-orally-available-btk-degrader-in-development-for-b-cell-malignancies

Presented new case studies demonstrating clinical responses in two patients with B cell malignancies, chronic lymphocytic leuke...

 blackberry-nurix-therapeutics-tesla-and-other-big-stocks-moving-higher-on-tuesday

U.S. stocks were lower, with the Dow Jones index falling over 200 points on Tuesday. Shares of BlackBerry Limited (NYSE: BB) ...

Core News & Articles

STAT6 is a key drug target in type 2 inflammation. Upon signing the agreement in December 2019, Sanofi made an upfront payment ...

 needham-reiterates-buy-on-nurix-therapeutics-maintains-31-price-target

Needham analyst Gil Blum reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $31 price target.

 needham-maintains-buy-on-nurix-therapeutics-maintains-31-price-target

Needham analyst Gil Blum maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $31 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION